Bioanalytical testing services market projected to reach $16.47 billion by 2036

The bioanalytical testing services market is expected to grow from an estimated $5.66 billion in 2025 to $16.47 billion by 2036, representing a compound annual growth rate (CAGR) of 10.2%.

Demand is driven by drug discovery, non-clinical research, clinical trials, and regulatory submission requirements. Pharmaceutical developers increasingly rely on external testing facilities to access specialized equipment, experienced researchers, and regulatory expertise without maintaining all functions in-house.

The complexity of modern therapeutics, such as antibody-drug conjugates, bispecific antibodies, and precision medicines, is increasing the need for specialized analytical methods. These complex drugs often require multiple distinct analytical approaches to measure components like unlinked drug parts and total antibody levels simultaneously.

Key market players include Labcorp Drug Development, Thermo Fisher Scientific (PPD business), and Charles River Laboratories. The industry is also influenced by regulatory frameworks such as ICH M10, which aims to harmonize analytical documentation for regulatory submissions across different regions.